Purple Biotech posts updated Jan 2026 presentation

Q: What is Exhibit 99.1 in Purple Biotech Ltd.’s Form 6-K?

Exhibit 99.1 to the Form 6-K is the “Purple Biotech Corporate Presentation January 2026”, an updated corporate presentation issued by Purple Biotech Ltd.

Q: When was the updated Purple Biotech corporate presentation issued?

The updated corporate presentation, “Purple Biotech Corporate Presentation January 2026,” was issued on January 12, 2026.

Accepted by SEC EDGAR 01/12/2026 - 07:18 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Purple Biotech Ltd. submitted a Form 6-K as a foreign private issuer to furnish an updated corporate presentation titled “Purple Biotech Corporate Presentation January 2026.” This presentation is included as Exhibit 99.1 and is intended to provide current information about the company in January 2026.

The report is formally authorized on behalf of Purple Biotech Ltd. and is signed by Chief Executive Officer Gil Efron, dated January 12, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Purple Biotech Ltd. (PPBT) file in this Form 6-K?

Purple Biotech Ltd. filed a Form 6-K as a foreign private issuer to furnish an updated company presentation titled “Purple Biotech Corporate Presentation January 2026.”

What is Exhibit 99.1 in Purple Biotech Ltd.’s Form 6-K?

Exhibit 99.1 to the Form 6-K is the “Purple Biotech Corporate Presentation January 2026”, an updated corporate presentation issued by Purple Biotech Ltd.

When was the updated Purple Biotech corporate presentation issued?

The updated corporate presentation, “Purple Biotech Corporate Presentation January 2026,” was issued on January 12, 2026.

Who signed the Form 6-K for Purple Biotech Ltd.?

The Form 6-K was signed on behalf of Purple Biotech Ltd. by Gil Efron, the company’s Chief Executive Officer.

Why did Purple Biotech Ltd. submit this Form 6-K?

Purple Biotech Ltd. submitted this Form 6-K to furnish its updated January 2026 corporate presentation as an exhibit for investors and regulators.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of January 2026

Commission File Number: 001-37643

PURPLE BIOTECH LTD.

(Translation of registrant’s name into English)

4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Purple Biotech

On January 12, 2026, Purple Biotech Ltd. (the “Company” or the “Registrant”) issued an updated Company presentation, “Purple Biotech Corporate Presentation January 2026”, which is attached hereto as Exhibit 99.1.

Exhibit
99.1		Purple Biotech Corporate Presentation January 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

January 12, 2026	PURPLE BIOTECH LTD.

	By:	/s/ Gil Efron
		Gil Efron
		Chief Executive Officer

Source: View Original Filing on SEC EDGAR